Yüklüyor......
A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease
BACKGROUND: Multicentric Castleman disease (MCD) is a rare, systemic lymphoproliferative disorder driven by interleukin (IL)-6 overproduction. Siltuximab, an anti-IL-6 monoclonal antibody, has demonstrated durable tumor and symptomatic responses in a multinational, randomized, placebo-controlled stu...
Kaydedildi:
Yayımlandı: | Oncotarget |
---|---|
Asıl Yazarlar: | , , , , , , , , , |
Materyal Türü: | Artigo |
Dil: | Inglês |
Baskı/Yayın Bilgisi: |
Impact Journals LLC
2015
|
Konular: | |
Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4745809/ https://ncbi.nlm.nih.gov/pubmed/26327301 |
Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|